Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Components (Tables)

v3.23.3
Balance Sheet Components (Tables)
9 Months Ended
Sep. 30, 2023
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Components of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

    

September 30,
2023

    

December 31,
2022

Accrued liabilities:

  

General and administrative

  

$

717

$

855

Clinical trial related costs

2,126

1,327

Non-clinical research and manufacturing operations

  

411

1,779

Payroll related

  

38

4,828

Other accrued expenses

  

11

34

Total Accrued liabilities

  

$

3,303

$

8,823